UROMOL

Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors

Coordinatore	AARHUS UNIVERSITETSHOSPITAL    more  Organization address address: NORREBROGADE 44 city: AARHUS postcode: 8000 contact info Titolo: Ms. Nome: Christina Cognome: Bak Pedersen Email: send email Telefono: +45 78455307 Fax: +45 7846 4455
Nazionalità Coordinatore	Denmark [DK]
Sito del progetto	http://www.uromol.eu/
Totale costo	3˙922˙796 €
EC contributo	2˙995˙347 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-02-01   -   2013-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AARHUS UNIVERSITETSHOSPITAL  Organization address address: NORREBROGADE 44 city: AARHUS postcode: 8000 contact info Titolo: Ms. Nome: Christina Cognome: Bak Pedersen Email: send email Telefono: +45 78455307 Fax: +45 7846 4455	DK (AARHUS)	coordinator	0.00
2	"AARHUS UNIVERSITETSHOSPITAL, SKEJBY"  Organization address address: Brendstrupgaardsvej 100 city: AARHUS N postcode: 8200 contact info Titolo: Ms. Nome: Birgit Cognome: Christensen Email: send email Telefono: +45 8949 5119 Fax: +45 8949 6018	DK (AARHUS N)	participant	0.00
3	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM  Organization address address: 's Gravendijkwal 230 city: ROTTERDAM postcode: 3015CE contact info Nome: Mark J. Cognome: V. Rotterdam Email: send email Telefono: 31104391929 Fax: 31104081020	NL (ROTTERDAM)	participant	0.00
4	FUNDACIO PUIGVERT  Organization address address: CALLE CARTAGENA 340-350 city: BARCELONA postcode: 8025 contact info Titolo: Dr. Nome: Ferran Cognome: Algaba Email: send email Telefono: +34 934169700 Fax: +34 934169730	ES (BARCELONA)	participant	0.00
5	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III  Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 contact info Titolo: Mr. Nome: Juan José Cognome: Collazo Nieto Email: send email Telefono: +34 917 328 000 Fax: +34 912 246 980	ES (MADRID)	participant	0.00
6	FUNDACION UNIVERSITARIA BALMES  Organization address address: SAGRADA FAMILIA 7 city: VIC (BARCELONA) postcode: 8500 contact info Titolo: Dr. Nome: Gora Cognome: Merseburger Email: send email Telefono: 34938861222 Fax: 34938891063	ES (VIC (BARCELONA))	participant	0.00
7	UNIVERSIDAD POMPEU FABRA  Organization address address: PLACA DE LA MERCE 10-12 city: BARCELONA postcode: 8002 contact info Titolo: Ms. Nome: Eva Cognome: Martin Email: send email Telefono: +34 935422140 Fax: +34 935422002	ES (BARCELONA)	participant	0.00
8	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Ms. Nome: Siw Cognome: Utterberg Email: send email Telefono: 461861000000 Fax: 4618559357	SE (UPPSALA)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe. New genomic methods have allowed identifying new markers with potential clinical application. However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alterations in tumor tissue and urine, as well as polymorphisms in immune response genes, are very promising biomarkers that predict a tumor being present in the bladder and its likelihood of progression to invade the muscle. Here, we propose to combine the best markers of bladder cancer outcome in a prospective multicenter validation study in Spain, the Netherlands, Sweden and Denmark as genetic predictors. Pre-validation of markers has been or will be made utilizing the world’s largest bladder cancer biobank (60,000 samples from 2500 patients). To achieve enough power to rapidly generate conclusive results, 2000 patients will consecutively be enrolled, and subjected to analysis, as well as follow-up for 2-4 years. The approach is a pre-defined, standard operating procedure based, prospective study with fixed end-points and testing relatively few independent variables on tumor tissue, urine and blood. To obtain a seamless introduction into the clinic we will use a mathematical approach in which the best markers are weighted based on disease models and nomogram construction, leading to a risk score applied to each patient at each visit. The team has a very strong track record in bladder cancer research, micro-array application, nomogram construction, and bio-banking. The validated biomarkers will lead to specific recommendations for changes in patient management based on the risk scores. We estimate saving of more than 40 mill Euros annually based on a reduced frequency of cystoscopies, as well as an increased survival and a better quality of life for the patients.'

Introduzione (Teaser)

Cancer clinicians need better tools when selecting treatments for patients. Validated biomarkers will lead to recommendations for improved patient management based on the risk scores.